dr. gralow on a comparison of toxicities and patient-stated preference in the swog s0307 trial
Published 10 years ago • 67 plays • Length 2:48Download video MP4
Download video MP3
Similar videos
-
2:33
dr. gralow gives an analysis of the apt trial
-
1:57
dr. gralow on adjuvant bisphosphonates for breast cancer
-
1:27
dr. julie gralow on the importance of genetic testing for breast cancer
-
2:45
dr shouse on the importance of ngs testing in follicular lymphoma
-
7:31
drs discuss sunekos & profhilo
-
5:12
thyroid update - 5 weeks post radioactive iodine
-
18:32
foods to avoid if you have graves' disease (these foods can harm your thyroid)
-
2:08
targeted breast cancer treatment, dr. julie gralow
-
2:01
dr. gralow on the use of bisphosphonates in early-stage breast cancer
-
1:56
dr. gralow on future research into bisphosphonates in breast cancer
-
12:27
julie r. gralow, md: swog so226 trial and bisphosphonates update
-
3:39
comparable outcomes, different toxicities with anastrozole, tamoxifen in dcis | ivana sestak
-
4:44
is anastrozole the new wonder drug? - with dr tasha
-
0:37
swog s1801: pathologic response in neoadjuvant-adjuvant vs. adjuvant pembro for resectable melanoma
-
6:55
fulvestrant versus anastrozole in patients with advanced breast cancer
-
1:15
which drug is more effective for the treatment of breast cancer: denosumab or bisphosphonates?
-
29:26
a diversity of diagnoses
-
1:14
julie gralow, md, shares her thoughts on new drugs in development for breast cancer.
-
4:54
comparison of prognostic tests in breast cancer
-
3:00
phase ii randomized trial of conventional vs hypofractionated post-mastectomy proton radiotherapy
-
6:57
anastrozole vs. letrozole for breast cancer: which aromatase inhibitor is the best?
-
3:14
factors that guide a metastatic breast cancer treatment decision